Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8440)	1/22/1999 6:53:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Different topic. Three cheers for Ellen Martin. Dealing with other I.R. departments leaves me thinking that probably only Martin and Xoma know what they are doing. It is almost a pleasure to not make money or even lose money with XOMA than to try to hold even a non intelligent conversation with other I.R. departments. Shareholders of biotechs, are long suffering and the industry had better wake up that better disclosure and treatment of stockholders is a must. The risk are very high, and anyone investing in a biotech should be able to feel that the I.R. department will be able to respond.

To: Bluegreen who wrote (8440)	1/22/1999 7:04:00 PM
From: opalapril	Read Replies (4) \| Respond to of 17367

<OFF AND ON TOPIC> OFF TOPIC: <<I am shocked that the U.K. can claim to have reduced mortality by 50% due to their early treatment campaign while the U.S. apparently remains in the dark about what can be done.>> The explanation is quite simple. Universal health care in the UK encourages early physician consult, detection, and treatment. The private health care/insurance mess we have in the USA keeps people away from doctors until they can't stand the pain anymore, for fear of being bankrupted, losing their insurance, or getting fired. BACK ON TOPIC: Does anyone else recall last Fall when, in the wake of the DSMB meeting, there was a Xoma public statement of some sort referring to the next planned December DSMB meeting and the possibility at that time of a "redesign" of the P-3 trial? I am working from an imperfect memory, again, but I recall the subject being raised and no real explanation being offered for how a "redesign" could occur at the end of a P-3 trial. With less than a year of operating funds left it seems to me even more bizarre to talk in terms of a "redesign" but I ask, anyway: what ever happened to the talk about redesigning the trial in December? Horrible to contemplate, but maybe...just maybe... Neuprex is simply no damn good? You have to admit Xoma's IR dept. isn't exactly acting like it's a wonder drug. More like a White House spin doctor getting dizzy over all the inconsistent stories they've invented. Everybody's doing it, so I will too: The above maunderings are mine alone and have no basis in fact or poetry but rather spring wholly from an anxious mind grown feverish and disturbed over the prospect of impending doom. Any resemblance to real companies, living or dead, is purely coincidental. The Xoma referred to does not exist. Bermuda is a fantasy. The FDA does not exist, either. The money you thought you invested actually was taken to Switzerland years ago, where it is resting nicely in a numbered account.